# Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)

> **NCT01374971** · PHASE3 · COMPLETED · sponsor: **Nathan Wei, MD, FACP, FACR:** · enrollment: 12 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Certolizumab Pegol (CZP)
- **PROCEDURE:** Arthroscopic synovial tissue biopsy

## Key facts

- **NCT ID:** NCT01374971
- **Lead sponsor:** Nathan Wei, MD, FACP, FACR:
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2014-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01374971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01374971, "Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01374971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*